Molecular studies have implicated mutant B-type Raf kinase (BRAF Mut ) of MAP-kinase signalling pathway in the pathogenesis of several cancers including colorectal cancer. Recently, the prognostic and therapeutic relevance of the most frequent BRAFV600E mutation also has been highlighted in colorectal carcinomas (CRC). Thus, the aim of this study was to investigate the prevalence of BRAFV600E mutation and to determine the correlation between this mutation and indicators of poor prognosis and outcome in patients with CRCs from Kashmir, North India. Here, we developed a highly sensitive technique, mutation allele-specific multiplex PCR (MASMP), for detection of BRAFV600E/BRAFc.1799T>A mutation, the results of which were confirmed by sequencing the product and compared to direct DNA sequencing. In total, BRAFV600E mutation status was analyzed in 57 colorectal tumour samples and an equal number of adjacent normal tissues. A high frequency of BRAFV600E mutation 21% (12/57) was identified in tumour tissues by MASMP compared to only 5.2% by direct DNA sequencing. Statistical analysis indicated that compared to BRAF-negative colorectal tumours, patients with BRAFV600E colorectal tumours were more likely to be >50 years old (61%) (P < 0.03). These tumours were more likely to be of clinical tumour stages III and IV (63%) (P < 0.04) with lymph node metastasis (52%) (P < 0.02) and characterised by a high-grade histology (63%) (P < 0.04). Colorectal patients harbouring BRAFV600E mutation experience more relapse/ recurrence (52%) (P < 0.02). We, therefore, conclude that BRAFV600E mutation can be used as an indicator of poor prognosis to predict the outcome for CRC patients from Kashmir. MASMP proved to be a simple, sensitive and reliable technique for screening patients for BRAFV600E mutation. Testing for this mutation may be useful for selecting initial therapy mode and for follow-up monitoring in CRC patients.
Introduction
Colorectal cancer shows geographical, racial and ethnic variation in its incidence. Globally, it is the third most prevalent cancer in men and women (1) . In 2016 alone, 134 490 new cases of colorectal cancer and 49 190 deaths from it have been reported worldwide (1) . Kashmir (North India), a relatively homogenetic ethnic and culturally unique Muslim-dominated population has been traditionally considered to be an endemic cancer zone with a peculiar cancer profile. Over past few years, an increase in incidence and occurrence of familial, early onset cancers has been reported in its unexplored ethnic population. The incidence rates for colorectal carcinoma (CRC) are 8.77/100 000 in males and 7.66/100 000 in females (2) . Regionally, the highest incidence has been reported for Srinagar district 6.19/100 000 (urban area) and lowest for Kupwara district (rural area) 1.59/100 000 (2) . As per our own hospital records [(Hospital cancer registry (HCR) of SMHS)], among all cancers colorectal cancer turns out to be the most commonly diagnosed cancer among females (16.8%) and second most commonly diagnosed cancer among males (16.4%) with a male:female ratio of 1.3:1 (3) . A number of risk factors have been associated with colon cancer and they include a family history of colon cancer, a personal history of colon cancer, long-standing inflammatory bowel disease, a personal history of colon polyps, obesity, smoking, sedentary lifestyle, a diet low in fruits and vegetables, race and ethnicity (4, 5) . The genesis of the disease is further complicated by the involvement of a number of driver genes responsible for chromosomal instability (CIN), microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and EMAST (elevated microsatellite alterations at selected tetranucleotide) in colorectal cancers, e.g. APC, hMLH1, MLH3, MMR, MSS, TP53, KRAS, BRAF and PI3KCA (6) (7) (8) .
BRAF (v-raf murine sarcoma viral oncogene homolog B1) is one of the three RAF genes encoding for cytoplasmic serine-threonine kinases, which are the main effectors of RAS/RAF/MEK/ERK signalling. Although more than 45 BRAF mutations have been identified in human cancers, about 90% of detected BRAF mutations are T>A transversions in exon 15 at nucleotide 1799(T1799A) leading to a valine>glutamic acid replacement at position 600 (BRAFV600E). BRAFV600E mutation occurs within its kinase domain, resulting in constitutive activation of the MAPK signalling pathway that leads to sustained proliferative signalling. BRAFV600E mutation has been implicated in the pathogenesis of several cancers, including melanomas (<50%), colorectal cancer (10%), papillary thyroid cancer (40%) and ovarian cancer (33%), non-small cell lung cancer (4%), prostate cancer (10%), Langerhans cell histiocytosis patients (∼57%) and hairy cell leukaemia (100%) (9) . Worldwide BRAF mutations have been reported in 5-22% of CRCs (8, 10) . Patients with BRAF-mutated CRC are generally older and female, and their tumours are more likely to have MSI, be higher grade, have more lymph node involvement, and have more advanced primaries (9) (10) (11) . Further, studies have shown that patients with BRAF Mut CRCs have shorter disease-free survival and worse overall survival (OS) after recurrence (11, 12) . New treatment options for patients with BRAF Mut CRC are evolving, e.g. use of Folfoxiri in firstline treatment seems to increase survival and combinations of EGFR inhibitors and BRAF/MEK inhibitors are promising (12, 13) .
Recognising the prognostic and therapeutic role of B-type Raf kinase (BRAF) mutations, the present study aims to estimate the prevalence of the most frequent BRAFV600E mutation and to determine the correlation between this mutation and indicators of poor prognosis and outcome in patients with CRC from Kashmir Valley, since such data from this region are not available in literature. Unlike conventional pre-screening mutational detection methods like Single Strand Conformational Polymorphism (SSCP), denaturing high performance liquid chromatography (DHPLC) etc, which are laborious, time consuming and need technical expertise, here we established a sensitive pre-screening BRAF mutational assessment method, mutation allele-specific multiplex PCR, which is simple, reproducible and applicable to large clinical research studies. The sensitivity of this technique proved to be much greater when compared with direct the DNA sequencing technique and it can be used as a reliable general screening tool for the identification of subset of cancer patients harbouring BRAFV600E mutations for suitable targeted therapeutic intervention.
Material and methods

Patient and samples
Patients attending the Surgical Gastroenterology Department at SMHS Hospital of Govt Medical College, Srinagar, Jammu and Kashmir, India, between February 2014 and December 2016 for CRC management were recruited for the study, with prior informed consent. Patients underwent histopathological examination of resected tumours to establish the clinical profile. Out of a total of 57 cases under study, surgically resected CRC tissue (which included tumour tissue and adjacent normal tissue) that were collected, 27 were rectal and 30 were proximal colon in origin. All tumours were adenocarcinomas. All samples were snap frozen at 70°C until analysis. The research work was approved by the Institutional Ethics Committee and the protocol followed for the study was in conformity with the Declaration of Helsinki (1964) developed by World Medical Association. A well-drafted questionnaire was used to collect information on clinico-epidemological characteristics such as age, family history of disease, smoking habits, site of tumour, clinical tumour stage and histopathological grade of tumour of the patients.
DNA isolation
High-molecular weight DNA was isolated from tissues samples of CRC patients by proteinase-K digestion and phenol/chloroform extraction (14) . The extracted genomic DNA was analysed by agarose gel electrophoresis using an UV illuminator.
PCR primers
The BRAF mutation primers (BRAF-mut) were designed based on the BRAF sequence, with a mismatched nucleotide at the 3ʹ end, such that wild-type BRAF was not amplified by them. The length of the PCR products was 126 bp. The BRAF sequencing primers (BRAF-seq) were also designed. In addition, TBXAS1 was chosen as a reference gene as an indicator for successful PCR amplification. Information concerning these primers is listed in Table 1 .
Mutation allele-specific multiplex PCR (MASMP)
BRAF-mut and TBXAS1 genes were amplified in the same 25 µl amplification system, which included 30 ng DNA templates, 10 pmol BRAF-mut primers, 5 pmol TBXAS1 primers, 0.1 mol/l dNTPs 
DNA sequencing
Purified PCR products of the samples showing mutant allele amplification (126 bp product) were sequenced using reverse primer. Also direct DNA sequencing of all tumour and adjacent controls samples, using sequencing primers, were performed in Automated DNA sequencer ABI prism 310. To minimise the sequencing artefacts induced by PCR, products from at least two different PCRs were sequenced using forward and reverse primers with Big Dye terminator cycle sequencing ready reaction mix (Applied Bio systems) based on fluorescence labelled dideoxy nucleotides as chain terminators. Purified single-stranded extension products were then resolved on ABI Prism 310 DNA sequencer. Sequences were compared by the BLAST program: www.ncbi.nim.nih.gov/BLAST/
Statistical analysis
All statistical analyses were performed using SPSS software. Odds ratio was used to determine association of presence of mutations with various clinico-epidemiological characteristics such as age, site of tumour, lymph node/s involved, family history, smoking habits, clinical tumour stage and histopathological grade of tumour. Statistical significance was considered when P < 0.05. The prevalence of BRAFV600E mutation in CRC was compared with that reported worldwide.
Results
Clinical data
Mean age of diagnosis was 51.2 ± 14.3 years in CRC patients; 38.5% (22/57) were less than 50 years and 61.4% (35/57) patients were in the age group >50 years representing the majority of cases in our study. Among the studied subjects, 45.6% (26/57) were males and 47.3% (31/57) were females with female:male ratio of 1.19. We observed a positive family history of 21.0% (12/57) in our study whereas positive smoking status corresponded to 71.9% (41/57). The most common site of lesion was proximal colon (n = 30). The majority of cases were of clinical tumour stage III 52.6% (30/57) followed by stage II 36.8% (27/57), and lymph node was involved in 52.6% (30/57) of the cases. Histopathological examination revealed that majority of cases, 54.3% (31/57), had moderately differentiated grade.
Mutation allele-specific multiplex PCR sensitivity detection
We assessed Brafc1799T>A/BRAFV600E mutation in 57 CRC tissues and in equal number of adjacent normal tissues as controls by MASMP (Figure 1 ). MASMP was repeated thrice for each sample. The thick band of 126 bp product was repeatedly coming in same samples only and not in controls or presumably BRAFV600E negative samples in the presence of 100bpTBXAS1 reference gene. The authenticity of MASMP in picking up the right product was confirmed by sequencing the product using reverse primer (Figure 2a and b) (shown by arrow). In order to investigate the sensitivity of the MASMP method, direct DNA sequencing of the exon15 of Braf gene in tumour samples was done. Whereas 21% (12/57) of the CRC samples were Brafc1799T>A positive by MASMP, only 5.2% were positive by the direct DNA sequencing method (Figure 3) . However, samples which were positive by MASMP included the ones that were positive by direct sequencing also. It has been demonstrated previously that allele-specific multiplex PCR detection sensitivity goes up to 1% whereas direct sequencing picks up only when 60% of the cells are tumours (15) . The same was found in this study.
Prevalence of BRAFV600E mutation in CRC samples
BRAFV600E mutation was detected in 21% (12/57) of CRCs by MASMP. No mutation was identified in the adjacent normal tissue of CRC samples. In addition, these results were confirmed by sequencing the product using reverse primer (Figure 2a and b) . A novel mutation Brafc.1795A>C that leads to threonine to proline variation at codon 599 (BRAF T599P) was identified in 3.5% (2/57) of tumour samples by sequencing using reverse primer (Figure 2a and b) (shown by small arrow). Association of BRAFV600E mutation status in CRC patients with clinico-pathological features is summarised in Table 2 . BRAFV600E mutation was associated with age, tumour stage, lymph node metastasis, grade and prognosis (P < 0.05). However, the frequency of the BRAFV600E mutation was not significantly correlated with gender, family history of cancer, smoking or location of the lesion (Table 2) .
Further investigation on large patient population is needed to elucidate whether BRAFT599P confer the same prognostic significance as BRAFV600E.
Discussion
BRAFV600E mutation detection in CRC patients from Kashmir valley revealed its presence in 21% of CRC samples and none in the adjacent normal tissues, indicating that this genetic event was likely to be among the key determinants of the colorectal cancer phenotype.
The occurrence and development of CRC involves multiple genetic abnormalities, with genetic alterations seen in EGFR/RAS/RAF signalling pathway. As per frequency, BRAF (5-22%) stands next to the Ras family (30-40%) with BrafV600E gene mutation as the most common variant (95%) that contributes to the destabilisation of the kinase encoded by the gene resulting in uncontrolled cell survival and proliferation (6) . BRAFV600E mutation frequency varies from 18 to 87% in different cancers and from 5 to 22% within CRC patients from geographically diverse regions (9, 10) . Of 57 colorectal cancers undergoing BRAF testing, 21% had BRAFV600E mutations which is consistent with that reported in the Swedish population (20.6%) but higher than that reported worldwide (5-12%) (10). Ethnic differences have been reported with BRAF mutations occurring at a higher frequency in White CRC patients (17%) versus Asian (4%) and Black 7% (8) . Our frequency results are consistent with the white population. The relatively high frequency of BRAFV600E mutation (21%) in CRC from Kashmir Valley could be due to its different ethnicity of its people, unique geographical locations of Kashmir, common lifestyle, common food habits with predominantly meat eating population and quite prevalent consanguineous marriage among Kashmiri population that predispose them genetically to many diseases. These results suggest the use of genomic approaches to elucidate the different ancestral determinants harboured by patient populations which may help more precisely and effectively treat colorectal cancer. Although some studies have indicated geographical and histological subtype classification factors may account for these differences, the reliability of the detection method must also be taken into consideration. In this study, MASMP proved relatively a sensitive technique than direct DNA sequencing demonstrating that this would be a reliable, sensitive, easy and robust method of detection in clinical samples (15, 16) .
Correlation analysis revealed that BRAFV600E mutant CRCs were characterised by unique clinico-epidemiological and pathologic characteristics. Although the absolute number in our study was small, several characteristic features of BRAFV600E mutant colon cancer have become apparent. Compared to patients with BRAF V600E negative tumours, patients with BRAFV600E positive colon cancers were more likely to be >50 years old (61 versus 38%, P < 0.03). Although not significant but casual a relationship between BRAFV600E mutated CRC and smoking habits, proximal colon site and rural origin of patients is evident from present study, which is in conformity with various other studies (4, 17, 18) . Furthermore, BRAFV600E mutant CRC tumours were more likely lymph node metastatic (P < 0.02) with clinical tumour stages III and IV (P < 0.04) and characterised by a high-grade histology (moderately differentiated, MD plus poorly differentiated, PD) (P < 0.04). Also, BRAFV600E mutant CRC patients experience more relapse/recurrence (P < 0.02). The present study demonstrates the significant association of BRAFV600E mutation with clinico-pathological features that are indicators of poor prognosis. These results are in inconformity with several studies conducted worldwide including clinical trials like PETACC-3 trial by Roth et al., the North Central Cancer Treatment Group (NCCTG) N0147 adjuvant study by Sinicrope et al. (19, 20) . BRAFV600E mutational status therefore proved to be strong predictor for OS. Patients with BRAFV600E mutant CRCs tend to have shorter disease-free survival and worse OS after recurrence (21) (22) (23) .
While cytotoxic chemotherapy remains central to the treatment for patients with metastatic CRC, there is a growing understanding that CRC is comprised of molecularly and clinically distinct populations that need different adjuvant treatment regimens. BRAFV600E mutant CRC is one such group. While BRAFV600E mutant advanced CRC patients do not benefit much from the addition of anti-EGFR mAbs to standard chemotherapy, Folfoxiri plus bevacizumab seems to generate better progression-free survival (PFS) and OS (12, 13) . Unlike melanomas, papillary thyroid carcinomas and myelomas that respond well to BRAF inhibitors (Vemurafenib), studies have shown controversial results with the use of BRAF inhibitors alone in case of metastatic CRCs (23) . The refractory response in terms of improvement in OS upon addition of BRAF inhibitors in the case of BRAFV600E positive metastatic CRC is possibly due to increased levels of PI3K/Akt activation and lower levels of MEK pathway activation (24, 25) . Inhibition of both the BRAF and PI3K pathways is therefore required in order to achieve desired improvement in PFS or OS (25) . Future studies, especially well-designed large randomised controlled trials conducted in BRAFV600E mutant CRC patients are urgently needed to find better treatment options for this subset of mCRC population. Further, we lack information on the biologically worst non-resectable mCRC cases due to lack of available tissue, which may introduce sample bias in studies like ours on CRC. Liquid biopsies with cell-free DNA analysis may in the future be a way to obtain molecular data from this large undescribed subgroup of mCRC patients.
Conclusion
BRAFV600E mutation can be used as an indicator of poor prognosis to predict the outcome of CRC patients, however further study on a larger patient population and a follow-up study is needed to substantiate the results of this study. MASMP proved to be simple, sensitive and reliable technique for screening patients for BRAF V600E mutation. Testing for this mutation may be useful for selecting initial therapy mode and for follow-up monitoring in CRC patients.
Funding
This work was supported by Indian Council of Medical Research (ICMR), New Delhi, India. 
